Table 2.
Demographic characteristics of patients with anti-GBM−mediated glomerulonephritis at first kidney transplantation
| Age, yr, median (P25−P75) | 43 (27-59) |
| Anti-GBM antibodies (n = 43) | 0 |
| Time between anti-GBM disappearance and kidney transplantation, mo, median (P25−P75) | 15 (8-31) |
| Donor deceased/living, n (%) | 44 (83)/9 (17) |
| Immunosuppressive regimen | |
| Induction (n = 46), n (%) | 28 (61) |
| Maintenance, n (%) | |
| Calcineurin inhibitors | 50 (96) |
| mTOR inhibitors | 4 (8) |
| MMF | 37 (71) |
| AZA | 13 (25) |
| Corticosteroids | 52 (100) |
AZA, azathioprine; GBM, glomerular basement membrane; MMF, mycophenolate mofetil; mTOR, mechanistic target of rapamycin; P25−P75, 25th−75th percentile.